Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Tremelimumab in Ovarian Cancer
NCT03249142Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Oct 2017
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in ovarian cancer, fallopian tube adenocarcinoma, primary peritoneal adenocarcinoma (PPC), sponsored by ARCAGY. Started Oct 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
ovarian cancerfallopian tube adenocarcinomaprimary peritoneal adenocarcinoma (PPC)
Beyond the preview
Go deeper on NCT03249142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249142.